As industry adoption of Dry Powder Inhaler (DPI) treatments continues to grow, drug developers need to balance powder performance characteristics with patient considerations. Historically, carriers have been used to facilitate flowability, aerosolization and dispersibility by attempting to keep small API particles from sticking to one another. However, a significant proportion of API often remains adhered to the carrier during inhalation. In order to achieve sufficient deep lung delivery, correspondingly larger doses may be required potentially leading to higher patient burden and lower compliance.
This Catalent webinar will explore how spray dried particles provide an attractive, carrier-free option for highly dispersed delivery of API to deep lung regions, utilizing an alternative approach to large, porous particles. The speakers will discuss how spray dry methodologies can generate light, low-density and aerodynamically favorable particles and will look at the technologies that are enabling high dose loading of DPI capsules.
Acorda Therapeutics will discuss their ARCUS® platform, geometric and aerodynamic particle size distributions (GPSD/APSD) and how they were able to make large, high surface area particles penetrate the lungs like small particles, enabling higher dosage. Catalent will talk about spray dry versus micronization for inhalation and explain how to optimize drying kinetics to maintain Target Product Profiles (TPPs) during scale-up activities. Catalent will also discuss more generally the impact that scale-up and tech transfer can have on the relationship between Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) based on experience from inhouse scale-up capabilities. Additionally, Catalent will also discuss techniques used to reduce processing steps and increase the Fine Particle Fraction (FPF). Lastly, Harro Hofliger will talk about using high-speed lines for spray dry powders, the associated challenges and how to optimize relevant process parameters.
Following the talk, the panel of industry experts will address Q&A in a roundtable format. Register early to submit your question to the panel!
ARCUS is a registered trademark of Acorda Therapeutics, Inc.
Key Learning Objectives
- Explore methods enabling higher dose loading
- Understand the advantages of spray drying for inhaled powders
- Address factors to consider for scale-up and powder handling
Target Audience
- Director or Senior Manager or VP of Formulation/Development
- Senior Scientist
- CMC Manager
- Principal Scientist
- Head of Formulation
- Project Leader
- Global Technology Director
- Senior Scientific Investigator
- CEO/CSO
- Operations or Quality
